Medication-related osteonecrosis of the jaw (MRONJ) is a rare, but well-documented, complication following the administration of anti-resorptive and anti-angiogenic drugs. MRONJ has a negative effect on quality of life, and can result in reduced social contact, pain and masticatory difficulties. Prescription of implicated medication is within the remit of GPs, and thus National Institute for Health and Care Excellence (NICE) guidelines have been published to inform prescribing. Careful consideration of the potential deleterious oral side-effects of these drugs is needed. NICE guidelines on the prescribing of bisphosphonates for osteoporosis acknowledge that osteonecrosis of the jaw was not included in the adverse events when the economic model was assessed. This article provides an overview of MRONJ, highlighting key areas for possible GP intervention when caring for patients at risk of developing MRONJ, and what to do if MRONJ is suspected.
Get full access to this article
View all access options for this article.
References
1.
EpsteinMSWicknickFWEpsteinJB, et al.(2010) Management of bisphosphonate-related osteonecrosis: Pentoxyfylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology110(5): 593–596. DOI: 10.1016/j.tripleo.2010.05.067.
GuarneriVMilesDRobertN, et al.(2010) Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Research and Treatment122(1): 181–188. DOI: 10.1007/s10549-010-0866-3.
4.
KahnSAKanisJAVasikaranS, et al.(1997) Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. Journal of Bone and Mineral Research12(10): 1700–1707. DOI: 10.1359/jbmr.1997.12.10.1700.
5.
KhanAAMorrisonAHanleyDA, et al.(2015) Diagnostic and management of osteonecrosis of the jaw: A systematic review and international consensus. Journal of Bone and Mineral Research30(1): 3–23. DOI: 10.1002/jbmr.2405.
6.
LoJCO’RyanFSGordonNP, et al.(2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. Journal of Oral and Maxillofacial Surgery68(2): 243–253. DOI: 10.1016/j.joms.2009.03.050.
7.
MariniFTonelliPCavalliL, et al.(2011) Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Frontiers in Bioscience (Elite Edition)1(3): 364–370. DOI: No: 10.2741/251.
8.
MarxRESawatariYFortinM, et al.(2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention and treatment. Journal of Oral and Maxillofacial Surgery63(11): 1567–1575. DOI: 10.1016/j.joms.2005.07.010.
RogersSNPalmerNOLoweD, et al.(2015) United Kingdom nationwide study of avascular necrosis of the jaw in bisphosphonate-related necrosis. The British Journal of Oral and Maxillofacial Surgery53(2): 176–182. DOI: 10.1016/j.bjoms.2014.11.008.
14.
RuggieroSLDodsonTBFantasiaJ, et al.(2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw- 2014 update. Journal of Oral and Maxillofacial Surgery72(10): 1938–1956. DOI: 10.1016/j.joms.2014.04.031.
15.
RuggieroSLFantasiaJCarlsonE (2006) Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology102(4): 433–441. DOI: 10.1016/j.tripleo.2006.06.004.
16.
SaadFBrownJEvan PoznakC, et al.(2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Annals of Oncology23(5): 1341–1347. DOI: 10.1093/annonc/mdr435.
17.
SammutSMaldenNLopesV, et al.(2016) Epidemiological study of alendronate-related osteonecrosis of the jaw in the southeast of Scotland. The British Journal or Oral and Maxillofacial Surgery54(5): 501–505. DOI: 10.1016/j.bjoms.2015.10.036.
TaylorTBryantCPopatS (2013) A study of 225 patients on bisphosphonates presenting to the bisphosphonate clinic at King’s College Hospital. British Dental Journal214(7): E18DOI: 10.1038/sj.bdj.2013.327.
20.
Thumbigere-MathVMichalowiczBSHodgesJS, et al.(2014) Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw. Journal of Periodontology85(2): 226–233. DOI: 10.1902/jop.2013.130017.
